Drug-Excipient Compatibility Studies In Binary Mixtures of Tadalafil by Using DSC, TGA and FTIR
Author:
DOĞANTÜRK Mahmut1ORCID, SEÇİLMİŞ CANBAY Hale2ORCID
Affiliation:
1. BURDUR MEHMET AKİF ERSOY ÜNİVERSİTESİ BİLİMSEL VE TEKNOLOJİ UYGULAMA VE ARAŞTIRMA MERKEZİ 2. BURDUR MEHMET AKİF ERSOY ÜNİVERSİTESİ, FEN-EDEBİYAT FAKÜLTESİ, KİMYA BÖLÜMÜ
Abstract
Objective: During drug preformulation studies, thermal analysis and spectroscopic techniques are used to detect physical or chemical incompatibilities between the active compound and the excipients in the formulation, and to demonstrate the safety and/or efficacy of the final product. It has revolutionized erectile dysfunction with the development of a selective cyclic guanosine monophosphate-specific PDE-5 inhibitors. Tadalafil is one of these inhibitors. Excipients are included in dosage forms to assist in manufacture, absorption or application. Although considered to be pharmacologically inert, the drug active compound may impair effectiveness.
Material and Method: DSC, TGA, and FTIR, were used in the work. Ascorbic acid, butylated hydroxyanisole, calcium phosphate dibasic, cellulose, magnesium stearate, mannitol, sodium carboxymethyl cellulose, sucrose, talc, starch, primojel, and citric acid exhibit interaction with Tadalafil. Binary mixtures of drug:excipient have been analyzed.
Results: Based on spectroscopic and thermal results; Tadalafil is incompatible with magnesium stearate, mannitol, sucrose, and ascorbic acid.
Conclusion: Studies to investigate drug-excipient compatibility are an important step in drug development studies. Thermal and spectroscopic techniques are widely used in such studies.
Publisher
SDU Journal of Health Sciences
Reference41 articles.
1. [1] Giuseppe, G. P., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I. M., Reid, L. M., Tuder, R. M. 2004. Pathologic assessment of vasculopathies in pulmonary hypertension. Journal of the American College of Cardiology, 43(12), 25-32. 2. [2] Rich, S. E. Primary pulmonary hypertension: executive summary from the World Symposium—primary pulmonary hypertension. http:// www.who.int/ncd/cvd/pph.html. 3. [3] Tanaka, S., Uchida, A., Hakamata, A., Miyakawa, S., Odagari, N., Inui, N., Watanabe, H., Namıkı, N. 2020. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. Pharmazie, 75, 236-239. 4. [4] Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., Stewart, D. J. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine, 328, 1732–1739. 5. [5] Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine, 353, 2148–2157.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|